CA-125 plus transvaginal ultrasound,
does it really help with Earlier detection and lower ovarian or tubal cancer mortality?
research showsPopulation screening with CA-125 and transvaginal ultrasound to lower ovarian cancer mortality is rated D. UKCTOCS randomized 202,638 women and analyzed 202,562; ovarian or tubal cancer mortality with multimodal screening was HR 0.96 (95% CI 0.83 to 1.10). PLCO randomized 78,216 and included 68,557 in the ovarian cancer analysis, with RR 1.18 (0.82 to 1.71). Both primary endpoints failed, but the confidence intervals do not exclude mortality reductions of 17% to 18%, so this is unproven rather than repeatedly refuted.
ads claimEarlier stage detection is presented as conclusive evidence of longer survival.
Useful facts when choosing a product
- This verdict concerns population screening of asymptomatic women at average risk.
- CA-125 can rise in benign disease and remain normal in early cancer.
Chamgap Semantic Classification Code
Candidate index · review held
P.ca-125-plus-transvaginal-ultrasound-ovarian-cancer-screening-in-asymptomatic-women-at-average-risk.diagnostic.earlier-detection-and-lower-ovarian-or-tubal-cancer-mortality.reduce.UNKProcedures, devices and tests > CA-125 plus transvaginal-ultrasound ovarian cancer screening in asymptomatic women at average risk > Diagnostic or screening > Earlier detection and lower ovarian or tubal cancer mortality > Reduction claim > Unknown
An automated migration candidate, not an issued permanent code; exact claim scope remains under review. This machine-generated migration candidate helps retrieval but is not a permanent assignment. The original verdict ID and URL remain authoritative.
What the research actually shows
UKCTOCS randomized 202,638 women and analyzed 202,562; ovarian or tubal cancer mortality with multimodal screening was HR 0.96 (95% CI 0.83 to 1.10). PLCO randomized 78,216 and included 68,557 in the ovarian cancer analysis, with RR 1.18 (0.82 to 1.71). Both primary endpoints failed, but respectively did not exclude 17% and 18% mortality reductions. No single pooled estimate combines the two papers.
Why this is classified as D (22)
Both large trials failed their primary endpoints, but the confidence intervals do not exclude mortality reductions of 17% to 18%, so the evidence is unproven, D, rather than repeatedly refuted, F, giving D with 22 points. No single pooled estimate combines the two papers.
Counterpoint. Evaluation of symptoms or inherited high risk is a separate clinical setting.
Rejudgment record. Cross-check applied — UKCTOCS randomized 202,638 and analyzed 202,562; MMS ovarian or tubal cancer mortality HR was 0.96 (95% CI 0.83 to 1.10). PLCO randomized 78,216 and included 68,557 in the ovarian cancer analysis; RR was 1.18 (0.82 to 1.71). Both primary endpoints failed, but 17% to 18% mortality reductions were not excluded, so this is unproven, D, rather than repeatedly refuted, F. No single pooled estimate combines the two papers.
Sub-claim grades by effect
This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.
| Effect (sub-claim) | Grade | Basis |
|---|---|---|
| Lower ovarian or tubal cancer mortality | D | Both primary endpoints failed but did not exclude reductions of 17% to 18%. |
| Reduction in advanced ovarian cancer | C | UKCTOCS showed a stage-shift signal that did not translate into lower mortality. |
| Earlier ovarian cancer detection | C | Earlier-stage detection increased, but overdiagnosis and null mortality remain. |
Cross-check — AI research and Codex final gate
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Menon U et al. 2021 | Long-term multicenter randomized population-screening trial | 202,638 randomized and 202,562 in the actual primary ITT analysis | NIHR, Cancer Research UK, The Eve Appeal, MRC, and the United Kingdom Department of Health; not manufacturer-led | Primary ovarian or tubal cancer mortality | MMS HR 0.96 (95% CI 0.83 to 1.10); primary endpoint failed. | Key direct evidence of nonproof |
| Buys SS et al. 2011 | PLCO randomized screening trial | 78,216 randomized and 68,557 in the ovarian cancer analysis | United States NCI public and intramural funding; not manufacturer-led | Ovarian cancer mortality | RR 1.18 (0.82 to 1.71); primary endpoint failed. | Independent evidence of nonproof |
Receipt — 2 References
All 2 cited sources were verified for existence at the original page (as of 2026-07-24).
Final verification and publication gate: Codex · Evidence date: 2026-07-24 · Corrections: none
Cite this verdict
[Chamgap] CA-125 plus transvaginal ultrasound x lower ovarian cancer mortality — Evidence Grade D·22. 2 cited sources checked. Source: https://chamgap.com/en/verdicts/womens/ca125-transvaginal-ultrasound-ovarian-cancer-screening-mortality/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.